FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W33468401> ?p ?o ?g. }

• W33468401 endingPage "1171" @default.
• W33468401 startingPage "1157" @default.
• W33468401 abstract "Major depressive disorder in children and adolescents is a significant problem and is also a predictive indicator of severe long-term difficulties.22, 43 Although the phenomenology of child and adolescent depression versus adult depression is held to be similar,51 child and adolescent depression has not been shown to clearly respond to treatment with tricyclic antidepressants (TCAs) in double-blind studies. More evidence may be available for children than for adolescents.1a, 19, 42 These generally negative findings have been reviewed,20 and the sudden unexplained deaths in children receiving desipramine29, 32, 33, 39 have caused widespread concern about use of TCAs in children and adolescents. Citing the lack of rigorous scientific evidence supporting the superiority of TCAs in child and adolescent depression compared with placebo, along with these sudden unexplained deaths, Geller17 and Werry52 have expressed concern about the routine use of TCAs in children and adolescents. As noted in the article by Labellarte and colleagues elsewhere in this issue, the emergence of selective serotonin reuptake inhibitors (SSRIs) has allowed for further psychopharmacologic methods for treating child and adolescent depression. Fluoxetine, fluvoxamine, sertraline, and paroxetine have been found in open studies to provide effective antidepressant activity without the sedating, anticholinergic, or cardiotoxic reactions observed with TCAs, although the incidence of insomnia, nervousness, restlessness, and anxiety are higher.4, 21, 50 McConville and colleagues25 found positive effects for sertraline in treating major depressive disorder in adolescents and also noted that scale ratings of depression frequently varied, being worsened by adverse events and improved by positive life circumstances. There may also be an emergence of an endogenous component in early childhood and adolescence, either as a pure syndrome or following repeated stressors.34 If repeated stressors can be shown to lead to a nonreactive pattern, a strong argument can be made for early psychopharmacologic and psychotherapeutic intervention in children and adolescents with major depressive disorders and double depressions (e.g., dysthymia and major depressive disorder). Follow-up of child and adolescent depressives suggests that these disorders can become long-term, causing debilitating problems, including not only depression but also impairment in psychosocial and educational functioning.23, 37 A few double-blind studies on SSRIs in child and adolescent depression have been conducted. Simeon and colleagues45a did not find statistically significant differences between fluoxetine versus placebo for depression; however, in an important study by Emslie and colleagues,12 in which 96 children and adolescents were treated with either fluoxetine or placebo, a significant difference was found among treated and untreated groups on the Children's Depression Rating Scale Revised36 and the Clinical Global Impression Scale for depression.28 In this study, placebo effect was similar to drug effect in the first week of outpatient treatment; however, over the 8-week period of the trial, significant differences emerged in the criteria noted earlier.3 Therefore, a significant difference in efficacy may exist among drug versus placebo studies for both TCAs and SSRIs in depressed children and adolescents provided that a sufficiently large sample is used in studies to indicate differences between placebo and drug response. In addition, careful measurements must be taken both within single centers and between centers to ensure inter-rater reliability. Although the current clinical preference is to use SSRIs rather than TCAs in the treatment of child and adolescent depression, the hard evidence for efficacy from controlled studies is minimal. Moreover, a connection between the clinical effectiveness of these medications and their degree of serotonin reuptake inhibition seems to be lacking. Further studies of the “traditional” TCAs and SSRIs are needed, including multidose studies of SSRIs in children and adolescents with depressive disorders; however, also needed is more exploration of newer or alternate antidepressive agents. The following section begins with an overview of these compounds and leads into a discussion of the most common alternate antidepressants used by practitioners, as well as some newer developments." @default.
• W33468401 created "2016-06-24" @default.
• W33468401 creator A5024355782 @default.
• W33468401 creator A5054576941 @default.
• W33468401 creator A5057415417 @default.
• W33468401 creator A5058445907 @default.
• W33468401 creator A5065543556 @default.
• W33468401 creator A5079463237 @default.
• W33468401 date "1998-10-01" @default.
• W33468401 modified "2023-09-27" @default.
• W33468401 title "NEWER ANTIDEPRESSANTS" @default.
• W33468401 cites W1493045979 @default.
• W33468401 cites W1754881187 @default.
• W33468401 cites W17910404 @default.
• W33468401 cites W1881281756 @default.
• W33468401 cites W1964727785 @default.
• W33468401 cites W1969766464 @default.
• W33468401 cites W1976768539 @default.
• W33468401 cites W1977866915 @default.
• W33468401 cites W1987445108 @default.
• W33468401 cites W1996117390 @default.
• W33468401 cites W2001254177 @default.
• W33468401 cites W2001448102 @default.
• W33468401 cites W2014292956 @default.
• W33468401 cites W2015713704 @default.
• W33468401 cites W2016063345 @default.
• W33468401 cites W2017734575 @default.
• W33468401 cites W2034063477 @default.
• W33468401 cites W2043408496 @default.
• W33468401 cites W2047691368 @default.
• W33468401 cites W2049588183 @default.
• W33468401 cites W2056911400 @default.
• W33468401 cites W2058224101 @default.
• W33468401 cites W2058753168 @default.
• W33468401 cites W2060935959 @default.
• W33468401 cites W2061271956 @default.
• W33468401 cites W2079142758 @default.
• W33468401 cites W2082719588 @default.
• W33468401 cites W2092354923 @default.
• W33468401 cites W2304477227 @default.
• W33468401 cites W2412588743 @default.
• W33468401 cites W41213254 @default.
• W33468401 cites W4249480096 @default.
• W33468401 doi "https://doi.org/10.1016/s0031-3955(05)70067-5" @default.
• W33468401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9884680" @default.
• W33468401 hasPublicationYear "1998" @default.
• W33468401 type Work @default.
• W33468401 sameAs 33468401 @default.
• W33468401 citedByCount "10" @default.
• W33468401 crossrefType "journal-article" @default.
• W33468401 hasAuthorship W33468401A5024355782 @default.
• W33468401 hasAuthorship W33468401A5054576941 @default.
• W33468401 hasAuthorship W33468401A5057415417 @default.
• W33468401 hasAuthorship W33468401A5058445907 @default.
• W33468401 hasAuthorship W33468401A5065543556 @default.
• W33468401 hasAuthorship W33468401A5079463237 @default.
• W33468401 hasConcept C118552586 @default.
• W33468401 hasConcept C126322002 @default.
• W33468401 hasConcept C139719470 @default.
• W33468401 hasConcept C162324750 @default.
• W33468401 hasConcept C170493617 @default.
• W33468401 hasConcept C187212893 @default.
• W33468401 hasConcept C2775864247 @default.
• W33468401 hasConcept C2776134451 @default.
• W33468401 hasConcept C2776867660 @default.
• W33468401 hasConcept C2777669559 @default.
• W33468401 hasConcept C2777828372 @default.
• W33468401 hasConcept C2778689640 @default.
• W33468401 hasConcept C2779177272 @default.
• W33468401 hasConcept C2779657639 @default.
• W33468401 hasConcept C2779910183 @default.
• W33468401 hasConcept C558461103 @default.
• W33468401 hasConcept C71924100 @default.
• W33468401 hasConceptScore W33468401C118552586 @default.
• W33468401 hasConceptScore W33468401C126322002 @default.
• W33468401 hasConceptScore W33468401C139719470 @default.
• W33468401 hasConceptScore W33468401C162324750 @default.
• W33468401 hasConceptScore W33468401C170493617 @default.
• W33468401 hasConceptScore W33468401C187212893 @default.
• W33468401 hasConceptScore W33468401C2775864247 @default.
• W33468401 hasConceptScore W33468401C2776134451 @default.
• W33468401 hasConceptScore W33468401C2776867660 @default.
• W33468401 hasConceptScore W33468401C2777669559 @default.
• W33468401 hasConceptScore W33468401C2777828372 @default.
• W33468401 hasConceptScore W33468401C2778689640 @default.
• W33468401 hasConceptScore W33468401C2779177272 @default.
• W33468401 hasConceptScore W33468401C2779657639 @default.
• W33468401 hasConceptScore W33468401C2779910183 @default.
• W33468401 hasConceptScore W33468401C558461103 @default.
• W33468401 hasConceptScore W33468401C71924100 @default.
• W33468401 hasIssue "5" @default.
• W33468401 hasLocation W334684011 @default.
• W33468401 hasLocation W334684012 @default.
• W33468401 hasOpenAccess W33468401 @default.
• W33468401 hasPrimaryLocation W334684011 @default.
• W33468401 hasRelatedWork W181660975 @default.
• W33468401 hasRelatedWork W1981398130 @default.
• W33468401 hasRelatedWork W2007329912 @default.

• next